Galmed Pharmaceuticals Ltd
GLMD
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.78M
Close$
$7.39
59.7% upside
Current Fair Value
59.7% upsideUndervalued by 59.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.78 Million |
|---|---|
| Enterprise Value | $1.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-19.12 |
| Beta | 0.67 |
| Outstanding Shares | 952,168 |
Return
| Return on Equity | -89.05% |
|---|---|
| Return on Assets | -62.04% |
| Return on Invested Capital | -64.36% |
Valuation & Multiples
| P/E Ratio | -0.34 |
|---|---|
| PEG | -3.67 |
| Price to Sales | - |
| Price to Book Ratio | 0.36 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-3.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 25, 2026
EPS Estimate
$-3.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galmed Pharmaceuticals Ltd
CEO: Allen Baharaff Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is ...